The resources of the “Top 20” companies of the US pharmaceutical
industry are considerable. Presently, there are > 30,000 sales
representatives, each of whom visits, on average, eight physicians
daily. If these sales representatives work for 200 days each year, then
it is reasonable to estimate that > 75 million “details” occur.
In addition to the myriad of other methods of access to physicians
(advertisements, direct mail, television, etc), these visits create an
enormous opportunity for guideline developers and for the